A Phase 1b/2 Study Evaluating the Safety and Efficacy of Canakinumab With Darbepoetin Alfa in Patients With Lower-Risk Myelodysplastic Syndromes (MDS) Who Have Failed Erythropoietin Stimulating Agents (ESA)
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1/2
- Enrollment
- 41 patients (estimated)
- Sponsors
- Moffitt Cancer Center
- Collaborators
- Novartis
- Tags
- Erythropoiesis-Stimulating Agent (ESA), Monoclonal Antibody, Red Blood Cell Stimulant
- Trial Type
- Treatment
- Last Update
- 1 month ago
- SparkCures ID
- 1493
- NCT Identifier
- NCT04798339
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.